CAR-T cells, green light for early-stage treatments for some lymphomas

The Food and Drug Administration (FDA) has approved the use of CAR-T-cell therapy in the United States at an earlier stage of treatment for large B-cell lymphomas. And this is not a regulatory decision. little account: CAR-T, so-called “living drugs”, are complex therapies, until now reserved for the treatment of some haematological tumors in a very advanced stage of the disease.